Arca Biopharma Inc (NASDAQ:ABIO) recently announced that Chicago’s American Heart Association Scientific Sessions selected its Atrial Fibrillation Burden (AFB) substudy for the Phase 2B GENETIC-AF clinical trial for a poster presentation. The sessions will take place between November 10 and 12, 2018. Arca is a biopharmaceutical company that applies an accurate medicine approach to develop cardiovascular disease-related genetically-targeted therapies. On behalf of the company, Duke University Medical Center’s Associate Professor of Medicine as well as Director of the Duke Center for Atrial Fibrillation, Jonathan Piccini will make the presentation at the Chicago session.
Phase 2B clinical trial presentation report spikes ABIO shares
Immediately after the announcement by ABIO about AHASS picking up its Phase 2B clinical trial data for presentation at the large Chicago’s healthcare conference, the shares of the company spiked and made its way into the green. Reports indicate that ABIO started off strongly in the pre-market early morning hours after the announcement of upcoming presentation.
The press release from ABIO stated that the presentation titled, “Phase II Trial of Pharmacogenetic Guided Beta-Blocker Therapy with Bucindolol vs. Metoprolol for the Prevention of Atrial Fibrillation/Flutter in Heart Failure: Genetic-Af Af Burden Substudy” will be available from November 11, 2018 onwards. The market trend shows that the news about the presentation worked overwhelmingly positively for the company.
It is mostly because the company is presenting its study report at a highly trusted event in the field of medicine in front of some of the biggest investors, key figures as well as partners. Also, acceptance of ABIO’s Phase II trial study data will instigate more confidence in the team of the company working against Atrial Fibrillation in patients with heart failure. That is one reason for the excitement among the investors and is pushing the ABIO stock in the upward direction in the stock market.
Things to watch ahead
Analysts are keeping a close eye on ABIO’s activity and continued work related to introducing new options for patients with Atrial Fibrillation. The presentation of data is sure to create a major ripple for the company in the stock market.